Shanghai Henlius Biotech Inc. (HKG: 2696), a biopharmaceutical company based in China, has announced the completion of the first patient dosing in a Phase I clinical study for HLX6018, a GARP/TGF-β1 compound monoclonal antibody (mAb). The drug is under development for the treatment of fibrosis-related diseases and has been tested in healthy subjects.
Non-clinical studies have demonstrated that HLX6018 possesses significant anti-pulmonary and renal fibrosis effects and exhibits good safety. The drug recently received clinical trial approval in China for the treatment of Idiopathic Pulmonary Fibrosis (IPF) last month.- Flcube.com
